TNFRSF18 and cancer: Treatment with adenovirus-based vaccine plus N-803, OX40, GITR, and IDO inhibitor resulted in decreased immunosuppression of Tregs in the TME, and then the inhibition of tumor growth and protection from cancer cells rechallenge in 4T1 and LL2 models.